Trial Profile
A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms EFFICACY-HF
- Sponsors CSL Vifor
- 02 Apr 2022 This trial has been completed in Germany (End Date: 31 Oct 2009) according to European Clinical Trials Database record.
- 28 Apr 2012 Additional trial location (Germany) identified as reported by European Clinical Trials Database.
- 08 Aug 2011 New trial record